Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057447 · ClinicalTrials.gov registry record · Phase 1
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
A Phase 1 study, sponsored by InterMune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00057447: Clinical Trial Phase 1 study, sponsored by InterMune.
NCT00057447 is a Phase 1 study that was terminated before completion, run by InterMune. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057447, a Phase 1 study, was terminated before completion, sponsored by InterMune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland
Interventions
- DRUG Rituximab
- DRUG Interferon Gamma-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
Why NCT00057447 stopped before completion
NCT00057447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00057447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057447 about?
NCT00057447 is a clinical study titled "Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients". Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and P...
What is the current status of trial NCT00057447?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2003-03. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00057447?
The interventions under investigation include: Rituximab (DRUG), Interferon Gamma-1b (DRUG).
Who is sponsoring clinical trial NCT00057447?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057447's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia